CN110177785A - 一种二氢异喹啉类化合物 - Google Patents

一种二氢异喹啉类化合物 Download PDF

Info

Publication number
CN110177785A
CN110177785A CN201880006642.9A CN201880006642A CN110177785A CN 110177785 A CN110177785 A CN 110177785A CN 201880006642 A CN201880006642 A CN 201880006642A CN 110177785 A CN110177785 A CN 110177785A
Authority
CN
China
Prior art keywords
butyl
base
alkyl
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880006642.9A
Other languages
English (en)
Other versions
CN110177785B (zh
Inventor
彭程
许庆
冯腾
吕遐师
赖小刚
崔睿
张绍云
韩健
龚超骏
蔡兆雄
周杨
邹罡
李丹彬
袁海卿
邬征
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Ark Biopharmaceutical Co Ltd
Original Assignee
Suzhou Ark Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59110846&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN110177785(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Suzhou Ark Biopharmaceutical Co Ltd filed Critical Suzhou Ark Biopharmaceutical Co Ltd
Publication of CN110177785A publication Critical patent/CN110177785A/zh
Application granted granted Critical
Publication of CN110177785B publication Critical patent/CN110177785B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C07D455/06Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine containing benzo [a] quinolizine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

本发明提供一种通式I的化合物:,其中:R是氢、C1‑6烷基中的任一种;R1是氢、氘、卤素、C1‑6烷基、C1‑6烷基氨基、C1‑6烷氧基中的任一种;R2是氢、氘、卤素、C1‑6烷基、被最少一个氟所取代的C1‑6烷基、C3‑7环烷基、C1‑6烷基氨基,C1‑6烷氧基、杂环烷基中的任一种;Ar是苯基、噻吩基、吡啶基、嘧啶基、吡嗪基、哒嗪基、吡啶‑2(1H)‑酮基、吡啶‑4(1H)‑酮基、吡咯基、吡唑基、噻唑基、1,2,3‑三唑基、1,2,4‑三唑基、咪唑基、四氮唑基、异噻唑基、噁唑基、异噁唑基、噻二唑基、噁二唑基、萘基、苯并噻吩基、吲哚基、苯并咪唑基、苯并噻唑基、苯并呋喃基、喹啉基、异喹啉基、喹唑啉基中的任一种;R3是氢、氘、卤素、氰基、C1‑6烷基、C3‑7环烷基、C1‑6烷基氨基、C1‑6烷氧基、杂环烷基中的任一种;R4是氢、氘、C1‑6烷基中的任一种;R5是氢、氘、C1‑6烷基、被最少一个氟所取代的C1‑6烷基、C3‑7环烷基中的任一种。本发明提供的化合物可以用于治疗和预防乙肝病毒感染。

Description

PCT国内申请,说明书已公开。

Claims (38)

  1. PCT国内申请,权利要求书已公开。
CN201880006642.9A 2017-01-13 2018-01-10 一种二氢异喹啉类化合物 Active CN110177785B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017100274433 2017-01-13
CN201710027443.3A CN106810548B (zh) 2017-01-13 2017-01-13 一种二氢异喹啉类化合物
PCT/CN2018/072057 WO2018130152A1 (zh) 2017-01-13 2018-01-10 一种二氢异喹啉类化合物

Publications (2)

Publication Number Publication Date
CN110177785A true CN110177785A (zh) 2019-08-27
CN110177785B CN110177785B (zh) 2022-02-08

Family

ID=59110846

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201910001831.3A Active CN109369640B (zh) 2017-01-13 2017-01-13 一种二氢异喹啉类化合物的制备方法
CN201710027443.3A Active CN106810548B (zh) 2017-01-13 2017-01-13 一种二氢异喹啉类化合物
CN201880006642.9A Active CN110177785B (zh) 2017-01-13 2018-01-10 一种二氢异喹啉类化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201910001831.3A Active CN109369640B (zh) 2017-01-13 2017-01-13 一种二氢异喹啉类化合物的制备方法
CN201710027443.3A Active CN106810548B (zh) 2017-01-13 2017-01-13 一种二氢异喹啉类化合物

Country Status (3)

Country Link
US (2) US10647712B2 (zh)
CN (3) CN109369640B (zh)
WO (1) WO2018130152A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066278A (zh) * 2017-06-01 2019-07-30 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
SG11201810834WA (en) 2016-06-10 2018-12-28 Enanta Pharm Inc Hepatitis b antiviral agents
WO2018019297A1 (zh) * 2016-07-29 2018-02-01 银杏树药业(苏州)有限公司 异喹啉酮类化合物及其制备抗病毒药物的应用
CN107759585A (zh) * 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
CN109369640B (zh) 2017-01-13 2020-03-27 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物的制备方法
IL272941B2 (en) 2017-08-28 2023-03-01 Enanta Pharm Inc Antiviral agents for viral hepatitis b
KR102705376B1 (ko) * 2017-10-05 2024-09-11 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학적 화합물
EP3694856B1 (en) * 2017-11-22 2023-10-25 Sunshine Lake Pharma Co., Ltd. Fused tricyclic compounds and uses thereof in medicine
US10428070B2 (en) 2017-12-06 2019-10-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10723733B2 (en) 2017-12-06 2020-07-28 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019177937A1 (en) 2018-03-12 2019-09-19 Arbutus Biopharma, Inc. Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
US10729688B2 (en) 2018-03-29 2020-08-04 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CA3096687A1 (en) 2018-04-12 2019-10-17 Arbutus Biopharma Corporation Methods for preparing substituted pyridinone-containing tricyclic compounds
EP3846808A4 (en) * 2018-09-05 2022-08-17 Children's Medical Center Corporation PAPD5 INHIBITORS AND METHODS OF USE THEREOF
BR112021005091A2 (pt) 2018-09-21 2021-06-08 Enanta Pharmaceuticals, Inc. heterociclos funcionalizados como agentes antivirais
CN110950860B (zh) * 2018-09-26 2023-03-31 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
JP2022511378A (ja) 2018-09-30 2022-01-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 縮合四環系化合物および医薬品におけるそれらの使用
CN113271946A (zh) 2018-11-21 2021-08-17 英安塔制药有限公司 官能化杂环化合物作为抗病毒剂
CN113999224B (zh) * 2019-01-08 2023-04-07 苏州爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
US11760755B2 (en) 2019-06-04 2023-09-19 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60197684A (ja) * 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔a〕キノリジン誘導体およびその塩
WO2015173164A1 (en) * 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
WO2016071215A1 (en) * 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN106810548A (zh) * 2017-01-13 2017-06-09 上海爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201605970QA (en) * 2014-01-30 2016-08-30 Hoffmann La Roche Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60197684A (ja) * 1984-03-21 1985-10-07 Dainippon Pharmaceut Co Ltd ベンゾ〔a〕キノリジン誘導体およびその塩
WO2015173164A1 (en) * 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
WO2016071215A1 (en) * 2014-11-03 2016-05-12 F. Hoffmann-La Roche Ag Novel 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN106810548A (zh) * 2017-01-13 2017-06-09 上海爱科百发生物医药技术有限公司 一种二氢异喹啉类化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110066278A (zh) * 2017-06-01 2019-07-30 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用

Also Published As

Publication number Publication date
CN106810548B (zh) 2019-02-15
US20200207755A1 (en) 2020-07-02
CN109369640B (zh) 2020-03-27
CN110177785B (zh) 2022-02-08
WO2018130152A1 (zh) 2018-07-19
CN106810548A (zh) 2017-06-09
US20190389855A1 (en) 2019-12-26
CN109369640A (zh) 2019-02-22
US10717730B1 (en) 2020-07-21
US10647712B2 (en) 2020-05-12

Similar Documents

Publication Publication Date Title
CN110177785A (zh) 一种二氢异喹啉类化合物
CN105246883B (zh) Dna‑pk抑制剂
CN110066278A (zh) 稠合三环类化合物及其在药物中的应用
EP4180431A1 (en) Chemical compounds
JP2017518276A (ja) ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物
CN104662033A (zh) 黄病毒科病毒的大环抑制剂
CN103228651A (zh) 可用作atr激酶抑制剂的化合物
CN106132950A (zh) 化合物和使用方法
CN103420991B (zh) 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
CN111315380A (zh) 凋亡信号调节激酶抑制剂及其用途
WO2019137201A1 (zh) 杂芳基并四氢吡啶类化合物、其制备方法、药物组合物及应用
WO2020020377A1 (zh) 用作fgfr4抑制剂的稠环衍生物
CN110272425A (zh) 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
JP2023145644A (ja) ジヒドロイソキノリン系化合物
CN115677684A (zh) 取代芳基或杂芳基类化合物
JP2023525829A (ja) 置換三環式アミド、その類似体、およびそれらを使用する方法
WO2021057994A1 (zh) 一种吡唑类化合物及其应用
KR20200037356A (ko) 피리다지논계 화합물, 그의 제조방법, 약학 조성물 및 용도
CN113662945B (zh) 用于治疗乙型肝炎的组合
TWI831325B (zh) 作為atr抑制劑的萘啶衍生物及其製備方法
WO2024046366A1 (zh) 选择性parp1抑制剂
TW202333715A (zh) 芳雜雙環化合物及其抗病毒用途
WO2024149314A1 (zh) 氨基噻吩类化合物、其制备方法及用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant